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Introduction
Although the treatment of chronic pain with opioid
agonists in cancer patients is widely accepted, the use
of opioid analgesics for patients with nonmalignant
pain has become widespread only in recent years,
and remains controversial (1,2). However, numerous
studies have shown that opioid agonists can safely
and effectively control chronic pain of moderate-to-
severe intensity (1,2).
Hydromorphone is a hydrogenated semi-synthetic
ketone of morphine that has been used for many years
to treat moderate-to-severe cancer pain, for which it
is regarded as an effective alternative to morphine
(3,4). Hydromorphone is available as an oral formula-
tion, but the short elimination half-life of this drug
(5) necessitates repeated dosing every 4–6 h for effect-
ive around-the-clock pain control. This need for
frequent dosing could lead to reductions in compli-
ance, which in turn could negatively impact treatment
outcomes and quality of life (6,7). The introduction
of long-acting opioid agonist formulations has provi-
ded an important treatment option for patients with
chronic pain, and studies have shown that long-acting
opioids can improve pain management and reduce
opioid-related side effects in comparison to immedi-
ate-release (IR) formulations (7).
An OROS
  formulation of hydromorphone was
developed recently. It utilises OROS
  Push-Pull
TM
osmotic pump technology (ALZA Corporation,
Mountain View, CA) to release hydromorphone at a
controlled rate for up to 24 h. Clinical pharmacoki-
netic analysis has shown that, in contrast to IR
hydromorphone, OROS
  hydromorphone produces
relatively constant steady-state concentrations for
24 h with much less peak-to-trough variation (8).
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SUMMARY
Background: The use of opioid analgesics for patients with chronic nonmalignant
pain is becoming more widely accepted, and long-acting formulations are an
important treatment option. Aim: To assess conversion to extended-release
OROS
  hydromorphone from previous stable opioid agonist therapy in patients
with chronic nonmalignant pain of moderate-to-severe intensity. Methods: In this
open-label multicentre trial, patients were stabilised on their previous opioid ther-
apy before being switched to OROS
  hydromorphone at a ratio of 5 : 1 (morphine
sulphate equivalent to hydromorphone hydrochloride). The OROS
  hydromorphone
dose was titrated over 3–16 days to achieve effective analgesia, and maintenance
treatment continued for 14 days. Results: Study medication was received by 336
patients; 66% completed all study phases. Stabilisation of OROS
  hydromorphone
was achieved by 94.6% of patients, the majority in two or fewer titration steps
(mean time, 4.2 days). Mean pain intensity scores, as determined by the Brief Pain
Inventory, decreased during OROS
  hydromorphone treatment (p £ 0.001). The
percentage of patients rating their pain relief as ‘good’ or ‘complete’ increased,
and the use of rescue analgesics for breakthrough pain decreased. The interference
of pain with everyday activities (e.g. walking or work), and the effects on mood
and enjoyment of life, also improved during the study (all p < 0.001). OROS
 
hydromorphone was well tolerated, and adverse events were those expected for
opioid agonist therapy. Conclusion: Patients with chronic nonmalignant pain who
had been receiving opioid therapy easily underwent conversion to OROS
  hydro-
morphone, with no loss of efﬁcacy or increase in adverse events.
What’s known
In contrast to immediate-release hydromorphone,
OROS
  hydromorphone produces relatively constant
steady-state concentrations for 24 h. Conversion
from previous opioid therapy can be easily achieved
without loss of pain control or increase in adverse
events using a morphine equivalents : OROS
 
hydromorphone conversion ratio of 5 : 1 (based on
preliminary results from a pooled analysis of two
open-label, repeated-dose studies; one in subjects
with malignant pain and one in subjects with
nonmalignant pain).
What’s new
The current report presents ﬁnal results of the
individual study conducted in patients with
nonmalignant pain. It demonstrates that conversion
can be achieved without loss of pain control or
increase in adverse events, and provides additional
evidence of the safety and efﬁcacy for the proposed
5 : 1 morphine equivalents : OROS
 
hydromorphone conversion ratio.
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  hydromor-
phone from previous opioid agonist treatment was
evaluated in an open-label, repeated-dose study. Pre-
liminary results were presented as part of a pooled
analysis, with a second study of identical design per-
formed in patients with chronic cancer pain (9). The
current report presents ﬁnal results of the individual
study in patients with nonmalignant pain.
Methods
Study design
The study was an open-label, repeated-dose, single-
treatment, multicentre trial conducted at 35 sites
throughout the USA and Canada. Its protocol was
approved by an Institutional Review Board at each
site, and all patients provided written informed con-
sent.
Before the administration of study medication,
patients were stabilised on their previous opioid
therapy for at least 3 days. Stabilisation was deﬁned
as ‡ 3 consecutive days when the total daily baseline
opioid dose remained unchanged, with £ 3 doses of
rescue medication required for breakthrough pain.
Patients were permitted to receive combinations of
opioid drugs during this phase, and nonopioid and
adjuvant analgesics also were allowed.
When stabilised, patients were switched to OROS
 
hydromorphone hydrochloride using a 5 : 1 conver-
sion ratio of morphine sulphate equivalent to hydro-
morphone hydrochloride (4,10,11,12), with no
washout or overlap of previous opioid therapy and
study medication. Patients stabilised on transdermal
fentanyl were converted on the basis of 8 mg/day
hydromorphone for each 25 lg/h of fentanyl, which
conservatively approximates the 5 : 1 conversion
ratio (13). For all patients, the minimum starting
dose of OROS
  hydromorphone was 8 mg/day.
After the switch, OROS
  hydromorphone was titra-
ted over a period of 3–16 days. Each dose of OROS
 
hydromorphone was given for at least 2 days to ensure
that steady-state blood levels of hydromorphone were
achieved (14). If more than two doses (or 7 mg) of
rescue medication (IR hydromorphone) were required
in a 24-h period, the dose of OROS
  hydromorphone
was increased by 25 to 100%. Patients who did not
achieve stable OROS
  hydromorphone dosing after
21 days were discontinued from the study. After stabi-
lisation on OROS
  hydromorphone, patients entered
a 14-day maintenance phase. Those who withdrew
from the study had their OROS
  hydromorphone
dose tapered over several days (50% reduction every
2 days) until discontinuation.
Patients were treated on an outpatient basis, with
ﬁve study visits over the treatment period. Stabilisa-
tion of prior opioid therapy began at visit 1 (baseline
evaluation). OROS
  hydromorphone titration started
at visit 2, and OROS
  hydromorphone maintenance
therapy began at visit 3. Visits 4 and 5 occurred at
the midpoint and end of the maintenance phase,
respectively.
During the study, IR hydromorphone could be
prescribed as rescue medication for breakthrough
pain, with the recommended dose generally ranging
from 10% to 15% of the basic daily OROS
  hydro-
morphone dose. No other opioid medication was
permitted after conversion; however, patients were
allowed to use nonopioid and adjuvant analgesics.
Patients
Study patients were adults (‡ 18 years of age) with
chronic nonmalignant pain and stable analgesic
requirements (daily opioid requirement of ‡ 45 mg
morphine equivalents). Exclusion criteria included
hypersensitivity to hydromorphone or other opioid
agonists; gastrointestinal disorders that could affect
the intake, absorption or transit of study medication;
signiﬁcant disorders of the central nervous system;
respiratory compromise; risk of serious decrease in
blood pressure with an opioid analgesic; signiﬁcant
organ or metabolic dysfunction; a history of drug or
alcohol abuse; requirement for radiation treatment;
pregnancy or lactation; and use of any investigational
drug within 30 days of study initiation.
Assessments
The efﬁcacy of OROS
  hydromorphone was assessed
using the Short Form of the Brief Pain Inventory
(BPI) (15). Pain intensity (worst, least and average)
over the previous 24 h was rated by patients on a
scale of 0 (no pain) to 10 (pain as bad as you can
imagine). Pain relief was rated on a scale of 0% (no
relief) to 100% (complete relief). The degree to
which pain interfered with general activity, mood,
walking ability, normal work, relationships with oth-
ers, sleep and enjoyment of life was rated on a scale
of 0 (no interference) to 10 (complete interference).
In addition, both patients and physicians rated the
general effectiveness of study medication on a ﬁve-
point scale (1, poor; 2, fair; 3, good; 4, very good; 5,
excellent). Safety monitoring was performed by
recording adverse events and study discontinuations
throughout the trial. Patients also underwent phys-
ical examination at baseline and end-point.
Statistical analysis
Changes in mean BPI pain intensity, pain relief and
pain interference ratings from visit 2 to end-point
(or the last observation carried forward from visit 3
or 4 for patients who withdrew) were assessed using
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differences in BPI ratings, a type I (a) error of 0.05
was assumed. Statistical signiﬁcance was set at
p £ 0.05. No adjustment for multiple testing was
applied.
Results
Patients
Overall, 366 patients with chronic nonmalignant pain
were enrolled; 336 of these received study medication
(30 withdrew during the prior opioid stabilisation
phase). The study was completed by 222 patients
(66%); 94 (28%) discontinued during the titration
phase and 20 (8%) during the maintenance phase.
Patient disposition is illustrated in Figure 1, and
baseline characteristics of treated patients are shown
in Table 1.
OROS
  hydromorphone dosing
The overall mean ± SD duration of OROS
  hydro-
morphone treatment was 24.2 ± 12.2 days, with 306
patients (91%) receiving study medication for more
than 7 days and 143 patients (43%) receiving it for
more than 25 days.
Three hundred and eighteen of the 336 treated
patients (94.6%) achieved a stable dose of OROS
 
hydromorphone during the titration phase. Overall,
the mean time to dose stabilisation was 4.2 ± 2.12
days. Stabilisation was achieved in two or fewer titra-
tion steps by 87% of patients [no titration, n ¼ 209
(66%); one or two titration steps, n ¼ 82 (26%);
Figure 2]. The mean ± SD dose of prior opioid ther-
apy at the end of the prior opioid stabilisation phase
was 154.5 ± 172.6 mg morphine equivalents, and the
mean starting daily dose of OROS
  hydromorphone
was 30.1 ± 37.9 mg, resulting in a mean conversion
ratio of 5.13 : 1. The mean daily dose of OROS
 
hydromorphone increased to 56.6 ± 63.3 mg at the
end of titration and to 70.1 ± 146.1 mg at the end of
the maintenance phase.
At the start of the OROS
  hydromorphone titra-
tion period, mean rescue medication requirements
were 4.8 ± 4.4 doses per day and 15.7 ± 20.5 mg per
day. The frequency of rescue medication use, but not
mean dose, declined during OROS
  hydromorphone
therapy (Table 2).
Figure 1 Patient disposition
Table 1 Demographic and baseline characteristics of
treated patients
OROS
  R
hydromorphone
(n = 336)
Mean ± SD age, years 48.2 ± 11.7
Sex, n (%)
Male 151 (45)
Female 185 (55)
Mean ± SD height (cm) 170.6 ± 11.0
Mean ± SD weight (kg) 81.4 ± 22.0
Type of pain, n (%)
Sympathetic 16 (5)
Musculoskeletal 174 (52)
Neuropathic 134 (40)
Other 12 (4)
Location of pain, n (%)
Back 195 (58)
Limbs 179 (53)
Face/head/neck 64 (19)
Torso 57 (17)
Previous opioid medication, n (%)
Codeine 10 (3)
Fentanyl 22 (7)
Hydrocodone 46 (14)
Hydromorphone 23 (7)
Meperidine 1 (0.3)
Methadone 21 (6)
Morphine 72 (22)
Oxycodone 133 (40)
Propoxyphene 6 (2)
Mean daily opioid requirement (mg)* 154.5
*Morphine equivalent at end of stabilisation phase.
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Mean BPI pain intensity ratings for pain at its worst,
pain at its least, average pain and pain right now all
decreased with OROS
  hydromorphone treatment
(from the end of previous opioid stabilisation to the
end of OROS
  hydromorphone treatment; all
p £ 0.001) (Figure 3). Patients’ assessment of pain
relief (BPI) also improved during OROS
  hydromor-
phone treatment, from 52.7 ± 22.5% at the end of
previous opioid stabilisation to 60.1 ± 23.9% at last
postbaseline assessment.
In addition to the improvement in pain intensity,
patients reported a decrease in the degree to which
pain interfered with their lives, as assessed by BPI
pain interference scores (all p < 0.001) (Figure 4).
Investigators rated the overall effectiveness of medi-
cation as very good or excellent for 9% of patients at
baseline (visit 2) and for 27% at the last assessment.
Similarly, more patients rated the overall effectiveness
of medication as very good or excellent at the last
assessment (26%) than at the beginning of OROS
 
hydromorphone titration (8%).
Safety and tolerability
During the study, adverse events were experienced by
79% of patients. The most common events were gas-
trointestinal symptoms (such as nausea, constipation
and vomiting) as well as headache, dizziness and som-
nolence (Table 3). The majority of these events were
mild or moderate in severity. Serious adverse events
were reported by 13 patients (4%), three of whom
experienced episodes of overdose related to patient
noncompliance with therapy. Two of these three
patients were withdrawn from the study, and all three
recovered with no sequelae. No other serious adverse
events were considered probably or deﬁnitely related
to study treatment. One death occurred during the
study, which resulted from a perforated ulcer in the
caecum of a patient with a history of morbid obesity.
This event was not considered related to the study
treatment. No clinically signiﬁcant changes in vital
signs occurred during the trial.
Discussion
Results of the previous interim pooled analysis showed
that patients with chronic malignant or nonmalignant
pain could be switched easily from previous opioid
Figure 2 Percentage of patients requiring titration steps
to achieve stabilisation of OROS
  hydromorphone dose
(n ¼ 318)
Table 2 Rescue medication (IR hydromorphone) used
by patients receiving daily OROS
  hydromorphone
No. daily doses Daily dose (mg)
Start of titration
Mean ± SD 4.8 ± 4.36 15.7 ± 20.47
End of titration
Mean ± SD 4.0 ± 6.04 14.3 ± 20.47
Mean change )0.9 )2.1
End of maintenance
Mean ± SD 4.1 ± 10.38 15.8 ± 42.54
Mean change )0.5 0.8
Figure 3 Comparison of BPI pain intensity ratings: end of previous opioid stabilisation phase vs. end of treatment. Scale:
0, no pain; 10, pain as bad as you can imagine (p £ 0.001 for all scores; no adjustment for multiple testing)
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  hydromorphone (9). This ﬁnding
was conﬁrmed by the ﬁnal results of the present study
in patients with chronic nonmalignant pain. The
majority of treated patients ( 95%) achieved a stable
dose of OROS
  hydromorphone, most of them (87%)
in two or fewer titration steps (4 days).
The efﬁcacy results of the present study indicate
that conversion from previous opioid therapy to
OROS
  hydromorphone can be achieved with no
loss of pain control. Over the course of OROS
 
hydromorphone treatment, patients’ BPI pain inten-
sity ratings (worst, least and average pain, and pain
right now) improved signiﬁcantly (p £ 0.001) in
comparison to the ratings recorded for their previous
opioid therapy. The improvement in pain interfer-
ence was similar. At the end of the maintenance per-
iod, there were statistically signiﬁcant (p < 0.001)
decreases in the degree to which patients’ pain inter-
fered with general activity, mood, ability to walk,
normal work, relationships with other people, sleep
and general enjoyment of life. Such improvement
can be expected to positively impact quality of life,
as has been demonstrated for extended-release for-
mulations of opioid agonists (7). A German study
conducted with a sustained-release formulation of
hydromorphone (Palladone) in 487 patients showed
improvement in quality of life domains, such as
sleep, vitality, mood, social contacts, activity, resili-
ence and walking ability (16), consistent with results
of the present study.
As has been demonstrated previously with exten-
ded-release morphine and oxycodone (17,18), con-
version to OROS
  hydromorphone was achieved
without the need for an intermediate IR opioid
phase. The conversion ratio used in the study
protocol is based on the commonly used 5 : 1
ratio of morphine equivalents to hydromorphone
(4,10,11,12). However, some investigators, including
the American Pain Society, recommend a reduction
in equivalent dose when introducing a new long-act-
ing opioid into treatment (19). The results of the
present study demonstrate that most patients can
successfully undergo direct conversion from their
previous opioid agonist therapy to OROS
  hydro-
morphone using the 5 : 1 ratio, with no loss of efﬁc-
acy or increase in side effects. Moreover, in the
majority of patients, conversion at this level requires
little or no titration to achieve stabilisation of the
OROS
  hydromorphone dose. Interestingly, even
fewer patients required dose titration in the study of
identical design in patients with chronic cancer pain
(104 manuscript in preparation). In that study, 77%
of patients achieved a stable OROS
  hydromor-
phone dose with no titration, and another 20%
required only one to two titration steps. In an analy-
sis of two studies in which an 8 : 1 ratio was used
for conversion, 70% of patients achieved a stable
dose of hydromorphone (20).
Figure 4 Comparison of BPI pain interference ratings: end of previous opioid stabilisation phase vs. end of treatment.
Scale: 0, no interference; 10, complete interference (p < 0.001 for all scores; no adjustment for multiple testing)
Table 3 Adverse events occurring in ‡ 5% of treated
patients (n ¼ 336)
Event No. patients (%)
Any adverse event 264 (79)
Nausea 79 (24)
Headache 61 (18)
Constipation 60 (18)
Dizziness 54 (16)
Vomiting 51 (15)
Somnolence 49 (15)
Pruritus 28 (8)
Sweating 22 (6)
Insomnia 20 (6)
Dry mouth 20 (6)
Diarrhoea 19 (6)
Fatigue 18 (5)
Peripheral oedema 17 (5)
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  hydromorphone was well tolerated
throughout the study. The most common adverse
events affected the gastrointestinal and central ner-
vous systems, and were consistent with those expected
to occur with opioid agonist therapy for chronic pain.
Limitations of the present study include the open-
label design and the lack of a control group. How-
ever, this study does show that patients can be
switched easily from stable opioid agonist therapy to
OROS
  hydromorphone, and that titration of
OROS
  hydromorphone will enable achievement of a
stable dose that maintains effective pain control. The
5 : 1 conversion ratio (morphine equivalents to
hydromorphone) also was well tolerated, with adverse
events typical of those expected for OROS
  opioid
agonist therapy. Based on these promising results, the
role of OROS
  hydromorphone in the treatment of
chronic nonmalignant pain should be further assessed
by prospective, randomised and controlled trials.
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